PMID- 25518417
OWN - NLM
STAT- MEDLINE
DCOM- 20150120
LR  - 20161125
IS  - 0047-1852 (Print)
IS  - 0047-1852 (Linking)
VI  - 72
IP  - 9
DP  - 2014 Sep
TI  - [Use of the urinary trypsin inhibitor ulinastatin for acute Kawasaki disease].
PG  - 1650-3
AB  - Intravenous immunoglobulin (IVIG) therapy is widely recognized as standard 
      treatment for Kawasaki disease(KD). However, about 20 % of KD patients are 
      resistant to IVIG and are considered to be a high risk group for coronary artery 
      lesions (CAL). Ulinastatin(UTI) is one of the neutrophil elastase inhibitors used 
      for patients with pancreatitis or circulatory shock, and several studies have 
      shown its efficacy for KD. Recently, we demonstrated that initial UTI treatment 
      combined with IVIG decreased the number of patients requiring addi- tional rescue 
      treatment and the occurrence of CAL. In this study, no severe adverse events 
      occurred. Further research and a prospective trial are needed to prove the 
      clinical efficacy and demonstrate the limits of UTI in patients with KD.
FAU - Kawamura, Yoichi
AU  - Kawamura Y
FAU - Kanai, Takashi
AU  - Kanai T
FAU - Takeshita, Seiichiro
AU  - Takeshita S
FAU - Nonoyama, Shigeaki
AU  - Nonoyama S
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Nihon Rinsho
JT  - Nihon rinsho. Japanese journal of clinical medicine
JID - 0420546
RN  - 0 (Glycoproteins)
RN  - 0 (Trypsin Inhibitors)
RN  - OR3S9IF86U (urinastatin)
SB  - IM
MH  - Acute Disease
MH  - Glycoproteins/adverse effects/*therapeutic use
MH  - Humans
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
MH  - Risk Factors
MH  - Trypsin Inhibitors/adverse effects/*therapeutic use
EDAT- 2014/12/19 06:00
MHDA- 2015/01/21 06:00
CRDT- 2014/12/19 06:00
PHST- 2014/12/19 06:00 [entrez]
PHST- 2014/12/19 06:00 [pubmed]
PHST- 2015/01/21 06:00 [medline]
PST - ppublish
SO  - Nihon Rinsho. 2014 Sep;72(9):1650-3.